Etcsembly Ltd is a limited liability company established in 2019, operating from its Atlas Building facility at Fermi Avenue, Didcot, Oxfordshire OX11 0QX. The company’s registration number is 12059749 and currently maintains active status. Etcbembly specializes in the research and development of novel immunotherapies with a focus on therapeutic innovation and design. The core business involves utilizing advanced artificial intelligence algorithms alongside bioengineering expertise to accelerate the discovery, validation, and optimization of new drug candidates targeting various immunological diseases. Etcsembly’s international presence is true, reflecting its collaborative efforts across global research institutions and pharmaceutical partners. The company employs a team of highly skilled scientists and engineers dedicated to complex projects within the SIC codes - 72110 (Research and experimental development on biotechnology) and potentially others depending on specific project activities. Etcsembly’s key focus is strategically positioned toward next-generation immunotherapies, aiming for significant advancements in precision medicine. The company values a strong international collaboration network, with hiring indicators confirming the recruitment of skilled professionals within its team.

Etcsembly Ltd is a limited liability company established in 2019, operating from its Atlas Building facility at Fermi Avenue, Didcot, Oxfordshire OX11 0QX. The company’s registration number is 12059749 and currently maintains active status. Etcbembly specializes in the research and development of novel immunotherapies with a focus on therapeutic innovation and design. The core business involves utilizing advanced artificial intelligence algorithms alongside bioengineering expertise to accelerate the discovery, validation, and optimization of new drug candidates targeting various immunological diseases. Etcsembly’s international presence is true, reflecting its collaborative efforts across global research institutions and pharmaceutical partners. The company employs a team of highly skilled scientists and engineers dedicated to complex projects within the SIC codes - 72110 (Research and experimental development on biotechnology) and potentially others depending on specific project activities. Etcsembly’s key focus is strategically positioned toward next-generation immunotherapies, aiming for significant advancements in precision medicine. The company values a strong international collaboration network, with hiring indicators confirming the recruitment of skilled professionals within its team.